What's Next? Trends and Opportunities in the Italian Pharmaceutical Industry.

Trends and opportunities of the Italian pharmaceutical industry, an overview of the market in the five-year period 2021-2026.

Market Analysis

The Italian pharmaceutical market has had a negative trend in recent years, recording constant growth in 2017, before experiencing a decline in 2019.

In 2021, the Italian pharmaceutical sector grew by 0.8%, recording a negative trend and weak growth due to the impact of the COVID-19 pandemic. The market grew in 2022 and is expected to grow slowly until 2025.

Unlike many other industries and businesses around the world that have suffered serious disruptions due to the COVID-19 pandemic, the pharmaceutical market has performed relatively well. Although national lockdowns and border restrictions have caused some supply problems, most companies have significant stocks to cope with such situations. Moreover, some of the major pharmaceutical companies have received substantial public and private investments to promote the development of vaccines capable of protecting against the virus and controlling its spread, which has likely offset the losses caused by the disruption of supply chains. This means that the COVID-19 pandemic has had a relatively minimal impact on the Italian pharmaceutical market.

Italy holds a 7.8% share of the European pharmaceutical market and in 2021 was the fourth largest market in Europe.

The market is expected to have a projected CAGR of 0.9% over the period 2021-26, which should lead the market to a value of 27.6 billion dollars by the end of 2026. In comparison, the French and German markets will grow at a CAGR of 3% and 5.1% respectively over the same period, reaching values of 84.3 and 102.7 billion dollars in 2026.

The market has been somewhat supported by the aging of the Italian population and the increase in age-related diseases, such as diabetes and cardiovascular diseases. Italy has one of the oldest populations in the world, with an average age of approximately 47.2 years. Almost 48% of the population is between the ages of 18 and 69, and over 32.8% are over 64 years old. This trend will continue to drive the demand for pharmaceutical products in the long term, which could help the market withstand further decline.

…